patient subgroup...
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
potential COVID-19 treatments - versus control - for COVID 19 outpatients
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.60 [0.36, 0.99]< 1 0% 14 studies (14/-) 97.8 % some concern low moderate crucial - deaths 0.73 [0.53, 1.01]< 1 0% 32 studies (32/-) 97.2 % low low high crucial - deaths (time to event analysis only) 0.80 [0.43, 1.50]< 1 0% 1 study (1/-) 75.7 % NA not evaluable crucial - hospitalization or death 0.50 [0.39, 0.63]< 1 67% 24 studies (24/-) 100.0 % low critical high crucial - A EFFACER PCR-negative (end of follow-up) 0.91 [0.57, 1.46]> 1 0% 1 study (1/-) 34.7 % NA not evaluable important - clinical deterioration 0.77 [0.61, 0.97]< 1 57% 11 studies (11/-) 98.7 % some concern critical moderate important - clinical improvement 1.12 [1.05, 1.19]> 1 0% 8 studies (8/-) 100.0 % some concern not evaluable moderate important - clinical improvement (14-day) 1.15 [0.94, 1.42]> 1 0% 4 studies (4/-) 91.0 % some concern not evaluable moderate important - clinical improvement (21-day) 1.28 [0.79, 2.10]> 1 0% 1 study (1/-) 84.1 % NA not evaluable important - clinical improvement (28-day) 1.43 [0.84, 2.44]> 1 76% 3 studies (3/-) 90.4 % low not evaluable high important - clinical improvement (7-day) 1.32 [0.44, 3.94]> 1 47% 2 studies (2/-) 69.0 % low not evaluable high important - clinical improvement (time to event analysis only) 1.17 [0.99, 1.37]> 1 81% 4 studies (4/-) 97.0 % low not evaluable high important - hospitalization 0.76 [0.66, 0.88]< 1 21% 29 studies (29/-) 100.0 % low low high important - mechanical ventilation 0.85 [0.55, 1.30]< 1 0% 6 studies (6/-) 77.6 % some concern not evaluable moderate important - Recovery (time to event analysis only) 1.23 [0.84, 1.80]> 1 94% 2 studies (2/-) 86.1 % low not evaluable high important - symptomatic Covid-19 0.56 [0.31, 1.00]< 1 0% 1 study (1/-) 97.6 % NA not evaluable important - viral clearance 0.92 [0.79, 1.07]> 1 31% 10 studies (10/-) 14.3 % some concern low moderate important - viral clearance by day 14 0.85 [0.70, 1.02]> 1 22% 4 studies (4/-) 4.1 % some concern not evaluable moderate important - viral clearance by day 7 0.93 [0.70, 1.23]> 1 57% 11 studies (11/-) 29.8 % low low high important - emergency room observation for > 6 hours or hospitalization 0.64 [0.47, 0.87]< 1 0% 1 study (1/-) 99.8 % NA not evaluable non important - ICU admission 0.72 [0.45, 1.15]< 1 0% 4 studies (4/-) 91.5 % some concern not evaluable moderate non important - recovery 1.05 [0.89, 1.24]> 1 69% 4 studies (4/-) 72.0 % some concern not evaluable moderate non important - 00 AE leading to drug discontinuation 0.79 [0.37, 1.69]< 1 60% 4 studies (4/-) 72.9 % some concern not evaluable moderate important - emergent treatment-resistant variants 0.64 [0.08, 4.94]< 1 67% 2 studies (2/-) 66.3 % some concern not evaluable moderate important - related AE (TRAE) 1.74 [1.51, 2.01]< 1 0% 2 studies (2/-) 0.0 % low not evaluable high important - related SAE (TRSAE) 1.01 [0.25, 4.05]< 1 0% 1 study (1/-) 49.6 % NA not evaluable important - serious adverse events 0.66 [0.49, 0.89]< 1 20% 7 studies (7/-) 99.6 % low not evaluable high important - adverse events 1.59 [0.86, 2.93]< 1 94% 10 studies (10/-) 6.8 % some concern low moderate non important -
LoD: level of statistical demonstration:
